Hartwig Medical Database
- Algorithms
- Billing code
- Biomarker
- Cancer of Unknown Primary
- cfDNA
- DNA
- Education
- End of Treatment
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Innovation
- IT
- Lab process
- Learning healthcare system
- Molecular diagnostics
- OncoAct
- oncoanalyser
- Participating hospitals
- Patients' stories
- Personalized treatment
- Quality
- Rare cancers
- Re-use data
- Research
- Scientific publications
- Treatment
- Uncategorized
- Whole genome sequencing
- Working in the cloud
A Learning Healthcare System for Better Cancer Research and Care
Vast amounts of data are generated during cancer diagnosis and treatment every single day. Tissue samples are analyzed, data about …
Requesting data from Hartwig Medical Foundation is now easier
As of September 1, 2026, the procedure for requesting data from the Hartwig Medical Database has been simplified. With this …
Metastatic bladder cancer: new insights into tumour spread and chemotherapy resistance
Hartwig data supports new Nature study on lethal metastatic bladder cancer. Researchers used the Hartwig Medical Database to independently validate …
Why genomes need clinical data: new Nature study uses Hartwig real world data to test a prostate cancer biomarker
Understanding prostate cancer’s clinical heterogeneity A new study in Nature investigates the mutational processes behind prostate cancer’s clinical heterogeneity and …
Hartwig advances precision oncology worldwide with oncoanalyser
Nicole Schonrock on scaling precision care for patients with cancer in Australia Hartwig Medical Foundation has developed powerful software for …
Biomarkers Reveal Which Cancer Patients Won’t Benefit From Treatment
Researchers from Vall d’Hebron Institute of Oncology identify genomic signals predicting non-response to cancer therapies in collaboration with Hartwig Medical …
GMS and Hartwig sign MOU to advance precision medicine for cancer patients
Genomic Medicine Sweden (GMS) and Hartwig Medical Foundation (Hartwig) today signed a Memorandum of Understanding (MoU). This MoU formalises a strategic partnership …
DataNexus connects clinical and genomic data
DataNexus is a project initiated by the Netherlands Cancer Institute–Antoni van Leeuwenhoek (NKI-AvL) to improve data availability by integrating clinical …
GENAYA Extended: More Care and Research
The GENAYA project has been extended by two years. This gives researchers more time to collect genetic tumor data from …
The value of the GENAYA project for patients of the future
The GENAYA project has been extended through 2028. A total of 39 hospitals now participate in the project, which is led by …
United in Unique – every individual story is unique
On World Cancer Day, attention is drawn worldwide to the impact of this disease This year’s theme, United in Unique, highlights the fact …
New research shows a more significant role of genetic predisposition in adults with glioblastoma
A recent study published in npj Genomic Medicine shows that hereditary predisposition in adult glioblastoma patients is more common than …
Blogs
Expansion of the Hartwig Client Portal: registration becomes easier, safer, and smarter
The expansion of the Hartwig Client Portal marks another important step in further digitizing the collaboration between Hartwig Medical Foundation …
Read more
How do you analyze 8,000 Tumor/Normal genomes in under two months?
It has been a long time coming: Hartwig Medical Foundation has transitioned to the GRCh38 (hg38) reference genome! For years, …
Read more
Medicines Policy must be based on real world data
The recent decision by the National Health Care Institute to re-evaluate expensive cancer medicines in real-world practice is a logical …
Read more
Cancer, a rare disease?
It may come as a surprise to many on this International Rare Disease Day (February 28), that a significant number …
Read more
If the practitioner doesn’t know where the primary tumor is located, they cannot offer a targeted treatment plan, and nor can they give the patient an estimate of their life expectancy.